VistaGen Therapeutics
Presença
VistaGen Therapeutics é uma empresa listada sob o símbolo VTGN (US).
Executivos
Veja o organograma con seus 23 executivos principais
Biografias mais buscadas da VistaGen Therapeutics
- Shawn Singh, Chief Executive Officer and Director
- Mary Rotunno, Director
- Maggie Fitzpatrick, Director
Criar um alerta
para seguir os movimentos de executivos da VistaGen Therapeutics.
Biotecnologia
VistaGen Therapeutics possui 2.298 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- AltruBio acaba de anunciar uma arrecadação de fundos de 225 milhões de dólares. (publicado em 24 de maio de 2024).
- Genmab adquiriu ProfoundBio (publicado em 23 de maio de 2024).
- Centivo has announced the acquisition of Eden Health (publicado em 23 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de VistaGen Therapeutics
- VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B | VistaGen Therapeutics, Inc
- VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit | VistaGen Therapeutics, Inc
- VistaGen to Participate at William Blair Biotech Focus Conference 2022 | VistaGen Therapeutics, Inc
- VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update | VistaGen Therapeutics, Inc
- VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022 | VistaGen Therapeutics, Inc
- VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting | VistaGen Therapeutics, Inc
- VistaGen to Participate in Upcoming June Investor Conferences | VistaGen Therapeutics, Inc
- VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Appoints Reid Adler as Chief Legal Officer | VistaGen Therapeutics, Inc
- View more press releases Close
Redes sociais sobre VistaGen Therapeutics
- VistaGen Therapeutics na Wikipedia, Google News e Yahoo Finance
- VistaGen Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Shawn Singh 
Ligue para a VistaGen Therapeutics em +1 212...
